Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Santin M, Casas S, Saumoy M, Andreu A, Moure R, Alcaide F, Ferrer E, Podzamczer D. Detection of latent tuberculosis by the tuberculin skin test and a whole-blood interferon-γ release assay, and the development of active tuberculosis in HIV-seropositive persons. Diagn Microbiol Infect Dis 2011;69:59-65. [PMID: 21146715 DOI: 10.1016/j.diagmicrobio.2010.09.005] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2010] [Revised: 08/30/2010] [Accepted: 09/06/2010] [Indexed: 10/18/2022]

For:	Santin M, Casas S, Saumoy M, Andreu A, Moure R, Alcaide F, Ferrer E, Podzamczer D. Detection of latent tuberculosis by the tuberculin skin test and a whole-blood interferon-γ release assay, and the development of active tuberculosis in HIV-seropositive persons. Diagn Microbiol Infect Dis 2011;69:59-65. [PMID: 21146715 DOI: 10.1016/j.diagmicrobio.2010.09.005] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2010] [Revised: 08/30/2010] [Accepted: 09/06/2010] [Indexed: 10/18/2022]

Number

Cited by Other Article(s)

Lu P, Lian Y, Li Z, Wu K, Xu Z, Xue H, Li J, Zhang X, Wang R, Ding X, Pan J, Ding H, Liu Q, Zhu L, Yang H. Effect of CD4 count on Mycobacterium tuberculosis infection rates in people living with HIV: a comparative study in prison and community. Sci Rep 2024;14:26386. [PMID: 39488608 PMCID: PMC11531519 DOI: 10.1038/s41598-024-77250-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2024] [Accepted: 10/21/2024] [Indexed: 11/04/2024] Open

Affiliation(s)

Peng Lu Department of Chronic Communicable Disease, Jiangsu Provincial Center for Disease Control and Prevention, 172 Jiangsu Rd, Nanjing, 210009, Jiangsu Province, People's Republic of China School of Public Health, Nanjing Medical University, Nanjing, Jiangsu Province, People's Republic of China
Yilin Lian School of Public Health, Southeast University, Nanjing, Jiangsu Province, People's Republic of China
Zhongqi Li Department of Chronic Communicable Disease, Jiangsu Provincial Center for Disease Control and Prevention, 172 Jiangsu Rd, Nanjing, 210009, Jiangsu Province, People's Republic of China
Kai Wu Central Hospital, Jiangsu Prison Administration, Changzhou, Jiangsu Province, People's Republic of China
Zhuping Xu Department of Chronic Communicable Disease, Wuxi City Center for Disease Control and Prevention, Wuxi, Jiangsu Province, People's Republic of China
Hao Xue Department of Chronic Communicable Disease, Yancheng City Center for Disease Control and Prevention, Yancheng, Jiangsu Province, People's Republic of China
Jincheng Li Department of Chronic Communicable Disease, Yangzhou City Center for Disease Control and Prevention, Yangzhou, Jiangsu Province, People's Republic of China
Xing Zhang Department of Chronic Communicable Disease, Changzhou City Center for Disease Control and Prevention, Changzhou, Jiangsu Province, People's Republic of China
Rong Wang Department of Chronic Communicable Disease, Nanjing City Center for Disease Control and Prevention, Nanjing, Jiangsu Province, People's Republic of China
Xiaoyan Ding Department of Chronic Communicable Disease, Jiangsu Provincial Center for Disease Control and Prevention, 172 Jiangsu Rd, Nanjing, 210009, Jiangsu Province, People's Republic of China
Jingjing Pan Department of Chronic Communicable Disease, Jiangsu Provincial Center for Disease Control and Prevention, 172 Jiangsu Rd, Nanjing, 210009, Jiangsu Province, People's Republic of China
Hui Ding Department of Chronic Communicable Disease, Jiangsu Provincial Center for Disease Control and Prevention, 172 Jiangsu Rd, Nanjing, 210009, Jiangsu Province, People's Republic of China
Qiao Liu Department of Chronic Communicable Disease, Jiangsu Provincial Center for Disease Control and Prevention, 172 Jiangsu Rd, Nanjing, 210009, Jiangsu Province, People's Republic of China.
Limei Zhu Department of Chronic Communicable Disease, Jiangsu Provincial Center for Disease Control and Prevention, 172 Jiangsu Rd, Nanjing, 210009, Jiangsu Province, People's Republic of China.
Haitao Yang Department of Chronic Communicable Disease, Jiangsu Provincial Center for Disease Control and Prevention, 172 Jiangsu Rd, Nanjing, 210009, Jiangsu Province, People's Republic of China

Collapse

Tian W, Han Z, Shi D, Wang H, Tang H, Wu Z, Zhang Y, Cui L, Shen N, Zheng J, Chen Y. Indeterminate Result of Interferon-γ Release Assay-A Risk Factor of Mortality for COVID-19 and Non-COVID-19 Respiratory Infections. J Med Virol 2024;96:e70058. [PMID: 39588785 PMCID: PMC11590174 DOI: 10.1002/jmv.70058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2024] [Revised: 09/28/2024] [Accepted: 10/29/2024] [Indexed: 11/27/2024]

Lu P, Wu K, Zhou H, Yu H, Yuan J, Dong L, Liu Q, Ding X, Lu W, Yang H, Zhu L, Martinez L. Evaluation of ESAT6-CFP10 Skin Test for Mycobacterium tuberculosis Infection among Persons Living with HIV in China. J Clin Microbiol 2023;61:e0181622. [PMID: 36946732 PMCID: PMC10117090 DOI: 10.1128/jcm.01816-22] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/23/2023] Open

Abstract

Recent global guidelines recommend Mycobacterium tuberculosis antigen-based skin tests, such as the ESAT6-CFP10 (EC) skin test, as acceptable alternatives to the tuberculin skin test (TST) and the QuantiFERON-TB Gold In-Tube test (QFT). However, the diagnostic value of these tests among persons living with HIV (PLHIV) is unknown. We aimed to assess the diagnostic accuracy of the EC among a cohort of PLHIV in China. We recruited PLHIV in Jiangsu Province, China, to assess sensitivity and specificity of the EC test. Participants were tested with the QFT, TST, and EC skin test. Results were stratified by age, M. tuberculosis BCG vaccination, and CD4 count. The sensitivity and specificity of the EC skin test was assessed using distinct cutoffs of the QFT and TST. Of 350 PLHIV enrolled in the study, 58 (16.6%), 89 (25.4%), and 59 (16.9%) tested positive with the EC test, the QFT, and the TST, respectively. Positivity increased with CD4 count; however, these trends were similar across tests. At a 5-mm cutoff, EC skin test specificity was high (99.6%, 95% confidence interval [CI] 95% CI = 97.7 to 100.0); however, sensitivity was moderate (81.4%; 95% CI = 66.6 to 91.6). After stratifying by BCG, the sensitivity and specificity were 86.4% (95% CI = 65.1 to 97.1) and 99.1% (95% CI = 95.0 to 100.0) among vaccinated PLHIV and 76.2% (95% CI = 52.8 to 91.8) and 100.0% (95% CI = 97.2 to 100.0) among unvaccinated PLHIV, respectively. Among PLHIV, the diagnostic value of the EC skin test remained high, regardless of BCG vaccination or CD4 count. The EC skin test performed comparably to TST and may be a valid alternative diagnostic test to use in settings or populations with high HIV prevalence and BCG vaccination. To our knowledge, this is the first study to evaluate the novel ESAT6-CFP10 skin test among PLHIV. Among 350 PLHIV, the test displayed high specificity and sensitivity, a finding which did not markedly differ based on BCG vaccination and CD4 count.

Collapse

Imeneo A, Alessio G, Di Lorenzo A, Campogiani L, Lodi A, Barreca F, Zordan M, Barchi V, Massa B, Tedde S, Crea A, Vitale P, Spalliera I, Compagno M, Coppola L, Dori L, Malagnino V, Teti E, Andreoni M, Sarmati L, Iannetta M. In Patients with Severe COVID-19, the Profound Decrease in the Peripheral Blood T-Cell Subsets Is Correlated with an Increase of QuantiFERON-TB Gold Plus Indeterminate Rates and Reflecting a Reduced Interferon-Gamma Production. Life (Basel) 2022;12:life12020244. [PMID: 35207531 PMCID: PMC8880410 DOI: 10.3390/life12020244] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Revised: 02/03/2022] [Accepted: 02/05/2022] [Indexed: 12/15/2022] Open

Affiliation(s)

Alessandra Imeneo Department of System Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy; (A.I.); (G.A.); (A.D.L.); (A.L.); (F.B.); (M.Z.); (V.B.); (B.M.); (S.T.); (A.C.); (V.M.); (M.A.); (L.S.)
Grazia Alessio Department of System Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy; (A.I.); (G.A.); (A.D.L.); (A.L.); (F.B.); (M.Z.); (V.B.); (B.M.); (S.T.); (A.C.); (V.M.); (M.A.); (L.S.)
Andrea Di Lorenzo Department of System Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy; (A.I.); (G.A.); (A.D.L.); (A.L.); (F.B.); (M.Z.); (V.B.); (B.M.); (S.T.); (A.C.); (V.M.); (M.A.); (L.S.)
Laura Campogiani Infectious Disease Clinic, Policlinico Tor Vergata, Viale Oxford 81, 00133 Rome, Italy; (L.C.); (P.V.); (I.S.); (M.C.); (L.C.); (L.D.); (E.T.)
Alessandra Lodi Department of System Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy; (A.I.); (G.A.); (A.D.L.); (A.L.); (F.B.); (M.Z.); (V.B.); (B.M.); (S.T.); (A.C.); (V.M.); (M.A.); (L.S.)
Filippo Barreca Department of System Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy; (A.I.); (G.A.); (A.D.L.); (A.L.); (F.B.); (M.Z.); (V.B.); (B.M.); (S.T.); (A.C.); (V.M.); (M.A.); (L.S.)
Marta Zordan Department of System Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy; (A.I.); (G.A.); (A.D.L.); (A.L.); (F.B.); (M.Z.); (V.B.); (B.M.); (S.T.); (A.C.); (V.M.); (M.A.); (L.S.)
Virginia Barchi Department of System Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy; (A.I.); (G.A.); (A.D.L.); (A.L.); (F.B.); (M.Z.); (V.B.); (B.M.); (S.T.); (A.C.); (V.M.); (M.A.); (L.S.)
Barbara Massa Department of System Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy; (A.I.); (G.A.); (A.D.L.); (A.L.); (F.B.); (M.Z.); (V.B.); (B.M.); (S.T.); (A.C.); (V.M.); (M.A.); (L.S.)
Simona Tedde Department of System Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy; (A.I.); (G.A.); (A.D.L.); (A.L.); (F.B.); (M.Z.); (V.B.); (B.M.); (S.T.); (A.C.); (V.M.); (M.A.); (L.S.)
Angela Crea Department of System Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy; (A.I.); (G.A.); (A.D.L.); (A.L.); (F.B.); (M.Z.); (V.B.); (B.M.); (S.T.); (A.C.); (V.M.); (M.A.); (L.S.)
Pietro Vitale Infectious Disease Clinic, Policlinico Tor Vergata, Viale Oxford 81, 00133 Rome, Italy; (L.C.); (P.V.); (I.S.); (M.C.); (L.C.); (L.D.); (E.T.)
Ilaria Spalliera Infectious Disease Clinic, Policlinico Tor Vergata, Viale Oxford 81, 00133 Rome, Italy; (L.C.); (P.V.); (I.S.); (M.C.); (L.C.); (L.D.); (E.T.)
Mirko Compagno Infectious Disease Clinic, Policlinico Tor Vergata, Viale Oxford 81, 00133 Rome, Italy; (L.C.); (P.V.); (I.S.); (M.C.); (L.C.); (L.D.); (E.T.)
Luigi Coppola Infectious Disease Clinic, Policlinico Tor Vergata, Viale Oxford 81, 00133 Rome, Italy; (L.C.); (P.V.); (I.S.); (M.C.); (L.C.); (L.D.); (E.T.)
Luca Dori Infectious Disease Clinic, Policlinico Tor Vergata, Viale Oxford 81, 00133 Rome, Italy; (L.C.); (P.V.); (I.S.); (M.C.); (L.C.); (L.D.); (E.T.)
Vincenzo Malagnino Department of System Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy; (A.I.); (G.A.); (A.D.L.); (A.L.); (F.B.); (M.Z.); (V.B.); (B.M.); (S.T.); (A.C.); (V.M.); (M.A.); (L.S.) Infectious Disease Clinic, Policlinico Tor Vergata, Viale Oxford 81, 00133 Rome, Italy; (L.C.); (P.V.); (I.S.); (M.C.); (L.C.); (L.D.); (E.T.)
Elisabetta Teti Infectious Disease Clinic, Policlinico Tor Vergata, Viale Oxford 81, 00133 Rome, Italy; (L.C.); (P.V.); (I.S.); (M.C.); (L.C.); (L.D.); (E.T.)
Massimo Andreoni Department of System Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy; (A.I.); (G.A.); (A.D.L.); (A.L.); (F.B.); (M.Z.); (V.B.); (B.M.); (S.T.); (A.C.); (V.M.); (M.A.); (L.S.) Infectious Disease Clinic, Policlinico Tor Vergata, Viale Oxford 81, 00133 Rome, Italy; (L.C.); (P.V.); (I.S.); (M.C.); (L.C.); (L.D.); (E.T.)
Loredana Sarmati Department of System Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy; (A.I.); (G.A.); (A.D.L.); (A.L.); (F.B.); (M.Z.); (V.B.); (B.M.); (S.T.); (A.C.); (V.M.); (M.A.); (L.S.) Infectious Disease Clinic, Policlinico Tor Vergata, Viale Oxford 81, 00133 Rome, Italy; (L.C.); (P.V.); (I.S.); (M.C.); (L.C.); (L.D.); (E.T.)
Marco Iannetta Department of System Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy; (A.I.); (G.A.); (A.D.L.); (A.L.); (F.B.); (M.Z.); (V.B.); (B.M.); (S.T.); (A.C.); (V.M.); (M.A.); (L.S.) Infectious Disease Clinic, Policlinico Tor Vergata, Viale Oxford 81, 00133 Rome, Italy; (L.C.); (P.V.); (I.S.); (M.C.); (L.C.); (L.D.); (E.T.) Correspondence:

Collapse

Dumitrescu F, Pisoschi CG, Pădureanu V, Stoian AC, Dragonu L, Giubelan L. The Role of QuantiFERON-TB Gold Plus in Mycobacterium Tuberculosis Detection in a Severe HIV Immunocompromised Patient-Case Report. Pathogens 2021;10:1523. [PMID: 34832677 PMCID: PMC8620343 DOI: 10.3390/pathogens10111523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2021] [Revised: 11/19/2021] [Accepted: 11/20/2021] [Indexed: 11/17/2022] Open

Solanich X, Fernández-Huerta M, Basaez C, Antolí A, Rocamora-Blanch G, Corbella X, Santin M, Alcaide F. Clinical Significance of Indeterminate QuantiFERON-TB Gold Plus Assay Results in Hospitalized COVID-19 Patients with Severe Hyperinflammatory Syndrome. J Clin Med 2021;10:jcm10050918. [PMID: 33652893 PMCID: PMC7956705 DOI: 10.3390/jcm10050918] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2021] [Revised: 02/18/2021] [Accepted: 02/23/2021] [Indexed: 12/13/2022] Open

Affiliation(s)

Xavier Solanich Department of Internal Medicine, Bellvitge University Hospital, 08907 L’Hospitalet de Llobregat, Barcelona, Spain; (A.A.); (G.R.-B.); (X.C.) Bellvitge Biomedical Research Institute (IDIBELL), 08907 L’Hospitalet de Llobregat, Barcelona, Spain; (M.F.-H.); (M.S.); (F.A.) Correspondence:
Miguel Fernández-Huerta Bellvitge Biomedical Research Institute (IDIBELL), 08907 L’Hospitalet de Llobregat, Barcelona, Spain; (M.F.-H.); (M.S.); (F.A.) Department of Microbiology, Bellvitge University Hospital, 08907 L’Hospitalet de Llobregat, Barcelona, Spain
Celeste Basaez Biochemistry Department, Hospital Interzonal General de Agudos Evita de Lanús, 1826 Lanús, Argentina;
Arnau Antolí Department of Internal Medicine, Bellvitge University Hospital, 08907 L’Hospitalet de Llobregat, Barcelona, Spain; (A.A.); (G.R.-B.); (X.C.) Bellvitge Biomedical Research Institute (IDIBELL), 08907 L’Hospitalet de Llobregat, Barcelona, Spain; (M.F.-H.); (M.S.); (F.A.)
Gemma Rocamora-Blanch Department of Internal Medicine, Bellvitge University Hospital, 08907 L’Hospitalet de Llobregat, Barcelona, Spain; (A.A.); (G.R.-B.); (X.C.) Bellvitge Biomedical Research Institute (IDIBELL), 08907 L’Hospitalet de Llobregat, Barcelona, Spain; (M.F.-H.); (M.S.); (F.A.)
Xavier Corbella Department of Internal Medicine, Bellvitge University Hospital, 08907 L’Hospitalet de Llobregat, Barcelona, Spain; (A.A.); (G.R.-B.); (X.C.) Bellvitge Biomedical Research Institute (IDIBELL), 08907 L’Hospitalet de Llobregat, Barcelona, Spain; (M.F.-H.); (M.S.); (F.A.) School of Medicine, Universitat Internacional de Catalunya, 08017 Barcelona, Spain
Miguel Santin Bellvitge Biomedical Research Institute (IDIBELL), 08907 L’Hospitalet de Llobregat, Barcelona, Spain; (M.F.-H.); (M.S.); (F.A.) Department of Infectious Diseases, Bellvitge University Hospital, 08907 L’Hospitalet de Llobregat, Barcelona, Spain Department of Infectious Diseases, University of Barcelona, 08907 L’Hospitalet de Llobregat, Barcelona, Spain
Fernando Alcaide Bellvitge Biomedical Research Institute (IDIBELL), 08907 L’Hospitalet de Llobregat, Barcelona, Spain; (M.F.-H.); (M.S.); (F.A.) Department of Microbiology, Bellvitge University Hospital, 08907 L’Hospitalet de Llobregat, Barcelona, Spain Department of Infectious Diseases, University of Barcelona, 08907 L’Hospitalet de Llobregat, Barcelona, Spain

Collapse

Chaisson LH, Saraceni V, Cohn S, Seabrook D, Cavalcante SC, Chaisson RE, Golub JE, Durovni B. CD4+ cell count stratification to guide tuberculosis preventive therapy for people living with HIV. AIDS 2020;34:139-147. [PMID: 31634189 PMCID: PMC7112158 DOI: 10.1097/qad.0000000000002398] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]

Overton K, Varma R, Post JJ. Comparison of Interferon-γ Release Assays and the Tuberculin Skin Test for Diagnosis of Tuberculosis in Human Immunodeficiency Virus: A Systematic Review. Tuberc Respir Dis (Seoul) 2017;81:59-72. [PMID: 29256218 PMCID: PMC5771747 DOI: 10.4046/trd.2017.0072] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2017] [Revised: 09/06/2017] [Accepted: 09/07/2017] [Indexed: 11/24/2022] Open

Lin AWC, Lau SKP, Woo PCY. Screening and treatment of latent tuberculosis infection among HIV-infected patients in resource-rich settings. Expert Rev Anti Infect Ther 2016;14:489-500. [PMID: 26999724 DOI: 10.1586/14787210.2016.1168693] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]

Ayubi E, Doosti-Irani A, Sanjari Moghaddam A, Sani M, Nazarzadeh M, Mostafavi E. The Clinical Usefulness of Tuberculin Skin Test versus Interferon-Gamma Release Assays for Diagnosis of Latent Tuberculosis in HIV Patients: A Meta-Analysis. PLoS One 2016;11:e0161983. [PMID: 27622293 PMCID: PMC5021339 DOI: 10.1371/journal.pone.0161983] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2016] [Accepted: 08/15/2016] [Indexed: 11/19/2022] Open

Santin M, García-García JM, Domínguez J. Guidelines for the use of interferon-γ release assays in the diagnosis of tuberculosis infection. Enferm Infecc Microbiol Clin 2016;34:303.e1-13. [PMID: 26917222 DOI: 10.1016/j.eimc.2015.11.022] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2015] [Accepted: 11/16/2015] [Indexed: 10/22/2022]

Detecting latent tuberculosis in compromised patients. Curr Opin Infect Dis 2016;28:275-82. [PMID: 25887610 DOI: 10.1097/qco.0000000000000158] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]

Khawcharoenporn T, Apisarnthanarak A, Phetsuksiri B, Rudeeaneksin J, Srisungngam S, Mundy LM. Tuberculin skin test and QuantiFERON-TB Gold In-tube Test for latent tuberculosis in Thai HIV-infected adults. Respirology 2014;20:340-7. [PMID: 25428131 DOI: 10.1111/resp.12442] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2014] [Revised: 09/19/2014] [Accepted: 09/25/2014] [Indexed: 12/20/2022]

Souza JMO, Evangelista MDSN, Trajman A. Added value of QuantiFERON TB-gold in-tube for detecting latent tuberculosis infection among persons living with HIV/AIDS. BIOMED RESEARCH INTERNATIONAL 2014;2014:294963. [PMID: 24991546 PMCID: PMC4058839 DOI: 10.1155/2014/294963] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 01/30/2014] [Accepted: 05/13/2014] [Indexed: 12/03/2022]

Whitworth HS, Aranday-Cortes E, Lalvani A. Biomarkers of tuberculosis: a research roadmap. Biomark Med 2013;7:349-62. [PMID: 23734796 DOI: 10.2217/bmm.13.53] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open

Redelman-Sidi G, Sepkowitz KA. IFN-γ release assays in the diagnosis of latent tuberculosis infection among immunocompromised adults. Am J Respir Crit Care Med 2013;188:422-31. [PMID: 23262514 PMCID: PMC12056979 DOI: 10.1164/rccm.201209-1621ci] [Citation(s) in RCA: 80] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2012] [Accepted: 11/28/2012] [Indexed: 01/18/2023] Open

Trajman A, Steffen RE, Menzies D. Interferon-Gamma Release Assays versus Tuberculin Skin Testing for the Diagnosis of Latent Tuberculosis Infection: An Overview of the Evidence. Pulm Med 2013;2013:601737. [PMID: 23476763 PMCID: PMC3582085 DOI: 10.1155/2013/601737] [Citation(s) in RCA: 81] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2012] [Accepted: 01/10/2013] [Indexed: 11/18/2022] Open

Diel R, Loddenkemper R, Nienhaus A. Predictive Value of Interferon-γ Release Assays and Tuberculin Skin Testing for Progression From Latent TB Infection to Disease State. Chest 2012;142:63-75. [DOI: 10.1378/chest.11-3157] [Citation(s) in RCA: 184] [Impact Index Per Article: 14.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open

Ruhwald M, Aabye MG, Ravn P. IP-10 release assays in the diagnosis of tuberculosis infection: current status and future directions. Expert Rev Mol Diagn 2012;12:175-87. [PMID: 22369377 DOI: 10.1586/erm.11.97] [Citation(s) in RCA: 103] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]

Kabeer BSA, Sikhamani R, Raja A. Comparison of interferon gamma-inducible protein-10 and interferon gamma-based QuantiFERON TB Gold assays with tuberculin skin test in HIV-infected subjects. Diagn Microbiol Infect Dis 2012;71:236-43. [PMID: 21996360 DOI: 10.1016/j.diagmicrobio.2011.07.012] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2011] [Revised: 07/06/2011] [Accepted: 07/25/2011] [Indexed: 12/31/2022]

Santin M, Muñoz L, Rigau D. Interferon-γ release assays for the diagnosis of tuberculosis and tuberculosis infection in HIV-infected adults: a systematic review and meta-analysis. PLoS One 2012;7:e32482. [PMID: 22403663 PMCID: PMC3293815 DOI: 10.1371/journal.pone.0032482] [Citation(s) in RCA: 112] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2011] [Accepted: 01/30/2012] [Indexed: 11/19/2022] Open

Abstract

BACKGROUND

Despite the widespread use of interferon-γ release assays (IGRAs), their role in diagnosing tuberculosis and targeting preventive therapy in HIV-infected patients remains unclear. We conducted a comprehensive systematic review to contribute to the evidence-based practice in HIV-infected people.

METHODOLOGY/PRINCIPAL FINDINGS

We searched MEDLINE, Cochrane, and Biomedicine databases to identify articles published between January 2005 and July 2011 that assessed QuantiFERON®-TB Gold In-Tube (QFT-GIT) and T-SPOT®.TB (T-SPOT.TB) in HIV-infected adults. We assessed their accuracy for the diagnosis of tuberculosis and incident active tuberculosis, and the proportion of indeterminate results. The search identified 38 evaluable studies covering a total of 6514 HIV-infected participants. The pooled sensitivity and specificity for tuberculosis were 61% and 72% for QFT-GIT, and 65% and 70% for T-SPOT.TB. The cumulative incidence of subsequent active tuberculosis was 8.3% for QFT-GIT and 10% for T-SPOT.TB in patients tested positive (one study each), and 0% for QFT-GIT (two studies) and T-SPOT.TB (one study) respectively in those tested negative. Pooled indeterminate rates were 8.2% for QFT-GIT and 5.9% for T-SPOT.TB. Rates were higher in high burden settings (12.0% for QFT-GIT and 7.7% for T-SPOT.TB) than in low-intermediate burden settings (3.9% for QFT-GIT and 4.3% for T-SPOT.TB). They were also higher in patients with CD4(+) T-cell count <200 (11.6% for QFT-GIT and 11.4% for T-SPOT.TB) than in those with CD4(+) T-cell count ≥ 200 (3.1% for QFT-GIT and 7.9% for T-SPOT.TB).

CONCLUSIONS/SIGNIFICANCE

IGRAs have suboptimal accuracy for confirming or ruling out active tuberculosis disease in HIV-infected adults. While their predictive value for incident active tuberculosis is modest, a negative QFT-GIT implies a very low short- to medium-term risk. Identifying the factors associated with indeterminate results will help to optimize the use of IGRAs in clinical practice, particularly in resource-limited countries with a high prevalence of HIV-coinfection.

Collapse

Fraisse P. Diagnostic des infections tuberculeuses latentes (sujets sains, sujets immunodéprimés ou amenés à l’être). Rev Mal Respir 2012;29:277-318. [DOI: 10.1016/j.rmr.2011.05.019] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2011] [Accepted: 05/11/2011] [Indexed: 01/30/2023]

Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J, Fielding K, Wilkinson RJ, Pai M. Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. THE LANCET. INFECTIOUS DISEASES 2012;12:45-55. [PMID: 21846592 PMCID: PMC3568693 DOI: 10.1016/s1473-3099(11)70210-9] [Citation(s) in RCA: 367] [Impact Index Per Article: 28.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]

Abstract

BACKGROUND

We aimed to assess whether interferon-γ release assays (IGRAs) can predict the development of active tuberculosis and whether the predictive ability of these tests is better than that of the tuberculin skin test (TST).

METHODS

Longitudinal studies of the predictive value for active tuberculosis of in-house or commercial IGRAs were identified through searches of PubMed, Embase, Biosis, and Web of Science and complementary manual searches up to June 30, 2011. Eligible studies included adults or children, with or without HIV, who were free of active tuberculosis at study baseline. We summarised incidence rates in forest plots and pooled data with random-effects models when appropriate. We calculated incidence rate ratios (IRR) for rates of disease progression in IGRA-positive versus IGRA-negative individuals.

FINDINGS

15 studies had a combined sample size of 26 680 participants. Incidence of tuberculosis during a median follow-up of 4 years (IQR 2-6), even in IGRA-positive individuals, was 4-48 cases per 1000 person-years. Seven studies with no possibility of incorporation bias and reporting baseline stratification on the basis of IGRA results showed a moderate association between positive results and subsequent tuberculosis (pooled unadjusted IRR 2·10, 95% CI 1·42-3·08). Compared with test-negative results, IGRA-positive and TST-positive results were much the same with regard to the risk of tuberculosis (pooled IRR in the five studies that used both was 2·11 [95% CI 1·29-3·46] for IGRA vs 1·60 [0·94-2·72] for TST at the 10 mm cutoff). However, the proportion of IGRA-positive individuals in seven of 11 studies that assessed both IGRAs and TST was generally lower than TST-positive individuals.

INTERPRETATION

Neither IGRAs nor the TST have high accuracy for the prediction of active tuberculosis, although use of IGRAs in some populations might reduce the number of people considered for preventive treatment. Until more predictive biomarkers are identified, existing tests for latent tuberculosis infection should be chosen on the basis of relative specificity in different populations, logistics, cost, and patients' preferences rather than on predictive ability alone.

FUNDING

Special Programme for Research and Training in Tropical Diseases (WHO), Wellcome Trust, Canadian Institutes of Health Research, UK Medical Research Council, and the European and Developing Countries Clinical Trials Partnership.

Collapse

Improving the diagnosis of tuberculosis: From QuantiFERON to new techniques to diagnose tuberculosis infections. Curr HIV/AIDS Rep 2011;8:153-63. [PMID: 21660459 DOI: 10.1007/s11904-011-0083-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]

Casas S, Muñoz L, Moure R, Castellote J, Guerra MR, Gonzalez L, Andreu A, Rafecas AG, Alcaide F, Santin M. Comparison of the 2-step tuberculin skin test and the quantiFERON-TB Gold In-Tube Test for the screening of tuberculosis infection before liver transplantation. Liver Transpl 2011;17:1205-11. [PMID: 22279622 DOI: 10.1002/lt.22375] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]

Abstract

The ability of interferon-gamma release assays (IGRAs) to detect latent tuberculosis (TB) infection before liver transplantation (LT)is not well established. The aims of this study were (1) to compare the ability of the tuberculin skin test (TST) and the QuantiFERON-TB Gold In-Tube (QFT-IT) test (a whole-blood IGRA) to diagnose latent TB infections in patients awaiting LT and (2) to correlate the results with the severity of liver disease. We conducted a prospective, cross-sectional study of patients who were evaluated for LT between July 2008 and July 2010. The 95 patients who were included underwent the 2-step TST and the QFT-IT test. The mean Model for End-Stage Liver Disease (MELD) score was 13.8. Forty-four patients (46.3%) had positive TST results, 42 (44.2%) had positive QFT-IT results, and 2 (2.1%) had indeterminate QFT-IT results. Simultaneous TST and QFT-IT testing yielded a positivity rate of 55.8% [95% confidence interval (CI) = 45.3-65.9] with either test, and the 2-step TST yielded a positivity rate of 46.3% (95% CI = 36.1-56.8); the difference was 9.5% (P = 0.004). In an adjusted analysis, the rates for positive TST results were lower in patients with MELD scores > or = 18 [odds ratio (OR) = 0.2, 95% CI = 0.04-0.7], lower in Child-Pugh-Turcotte (CPT) class C patients versus CPT class A patients (OR = 0.1, 95% CI = 0.02-0.6), and higher in males (OR = 6.4, 95% CI = 1.9-22.0). In contrast, only being male (OR = 3.5, 95% CI = 1.1-11.0) was associated with positive QFT-IT results; no association was found with the MELD score (OR = 0.8, 95% CI = 0.2-2.8) or the CPT class (OR = 0.3; 0.05-1.4). In conclusion, the QFT-IT test is better than the TST for detecting latent TB infection in patients with more advanced liver disease. Our results support the regular use of the QFT-IT test for screening patients with end-stage liver disease for latent TB infection before LT.

Collapse

Talati NJ, Gonzalez-Diaz E, Mutemba C, Wendt J, Kilembe W, Mwananyanda L, Chomba E, Allen S, del Rio C, Blumberg HM. Diagnosis of latent tuberculosis infection among HIV discordant partners using interferon gamma release assays. BMC Infect Dis 2011;11:264. [PMID: 21962029 PMCID: PMC3198954 DOI: 10.1186/1471-2334-11-264] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2011] [Accepted: 09/30/2011] [Indexed: 11/10/2022] Open

Santín Cerezales M, Benítez JD. Diagnosis of tuberculosis infection using interferon-γ-based assays. Enferm Infecc Microbiol Clin 2011;29 Suppl 1:26-33. [DOI: 10.1016/s0213-005x(11)70015-5] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]